


PREVALENCE of **LIVER cancer** in SWITZERLAND

Figure 1. Observed and projected number of patients having been diagnosed with malignant cancer of the liver and intrahepatic bile duct by index year and years since diagnosis.



**Table 1. Malignant cancer of the liver and intrahepatic bile duct (ICD-10 C22).
Limited-duration prevalence in Switzerland by sex, age and year.**

		Limited-duration prevalence ²															
		Men								Women							
		2000		2005		2010		2015		2000		2005		2010		2015	
Age ³	Time since diagnosis [years]	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹
0-49	up to 2	26	1.1	48	2.0	35	1.4	30	1.2	7	0.3	21	0.9	15	0.6	12	0.5
	up to 5	42	1.7	66	2.7	51	2.0	47	1.8	17	0.7	32	1.3	18	0.7	15	0.6
	up to 10	48	2.0	86	3.5	64	2.5	61	2.3	23	1.0	36	1.5	26	1.1	23	0.9
	2 to 5	16	0.6	18	0.7	16	0.6	17	0.7	10	0.4	11	0.5	3	0.1	3	0.1
	5 to 10	6	0.3	19	0.8	13	0.5	13	0.5	7	0.3	4	0.2	9	0.4	8	0.3
50-59	up to 2	54	11.6	88	18.1	114	21.4	118	19.5	17	3.7	21	4.2	29	5.5	35	6.0
	up to 5	85	18.2	139	28.4	155	29.2	163	27.0	24	5.0	32	6.6	36	7.0	46	7.7
	up to 10	94	20.0	161	32.9	195	36.7	205	33.9	33	7.0	40	8.3	47	8.9	56	9.6
	2 to 5	31	6.6	50	10.3	41	7.8	45	7.5	6	1.3	12	2.4	7	1.4	10	1.8
	5 to 10	8	1.8	22	4.5	40	7.5	42	6.9	9	2.0	8	1.7	10	2.0	11	1.8
60-69	up to 2	98	31.1	140	38.5	181	43.3	190	42.6	21	5.9	39	10.1	35	7.9	42	9.0
	up to 5	130	41.1	197	54.3	274	65.4	303	67.9	30	8.5	57	14.6	47	10.8	61	13.2
	up to 10	142	45.0	238	65.6	322	77.0	362	81.2	34	9.7	68	17.5	64	14.6	82	17.7
	2 to 5	32	10.0	57	15.8	93	22.1	113	25.4	9	2.6	17	4.5	12	2.8	19	4.2
	5 to 10	12	3.9	41	11.4	48	11.6	59	13.2	4	1.2	11	2.9	17	3.8	21	4.5
70-79	up to 2	70	33.5	137	60.3	128	51.2	153	52.2	36	12.3	56	18.5	60	19.4	63	18.5
	up to 5	122	58.3	187	81.8	217	86.5	259	88.6	44	14.9	75	25.1	77	24.8	83	24.2
	up to 10	126	59.8	200	87.8	281	111.9	320	109.3	46	15.6	86	28.6	97	31.1	102	29.7
	2 to 5	52	24.8	49	21.5	88	35.3	107	36.5	7	2.5	20	6.6	17	5.4	20	5.7
	5 to 10	3	1.5	14	6.0	64	25.4	61	20.7	2	0.7	10	3.5	20	6.3	19	5.4
80+	up to 2	38	39.4	40	35.3	50	38.0	56	37.0	20	9.9	16	7.1	22	9.1	17	6.4
	up to 5	48	49.7	46	40.9	82	62.2	88	57.9	25	12.7	26	11.5	31	12.6	28	10.7
	up to 10	52	54.1	46	40.9	93	71.1	103	67.8	25	12.7	36	16.3	38	15.6	38	14.6
	2 to 5	10	10.2	6	5.7	32	24.2	32	20.9	5	2.7	10	4.3	8	3.4	11	4.3
	5 to 10	4	4.5	0	0.0	12	8.9	15	9.9	0	0.0	11	4.8	7	3.0	10	3.9
All ages	up to 2	287	8.1	454	12.4	508	13.1	547	13.4	100	2.7	152	4.0	161	4.0	169	4.1
	up to 5	427	12.1	635	17.4	778	20.1	861	21.1	139	3.8	221	5.8	209	5.2	232	5.6
	up to 10	461	13.1	731	20.0	955	24.6	1050	25.8	161	4.4	266	7.0	272	6.8	301	7.2
	2 to 5	140	4.0	181	5.0	271	7.0	314	7.7	39	1.0	69	1.8	48	1.2	63	1.5
	5 to 10	35	1.0	96	2.6	177	4.6	189	4.7	22	0.6	45	1.2	63	1.6	68	1.6

¹ Proportion per 100'000

² Estimated with Counting/Projection-Method (see chapter B and C in document "Prevalence estimation methods")

³ Age at index date

[Complete prevalence not estimated (see "Prevalence estimation methods", chapter D.4.)]

May 2014

Contact: Matthias Lorez, PhD MAS
Foundation National Institute for Cancer Epidemiology and Registration (NICER)
c/o Universität Zürich
Seilergraben 49
CH-8001 Zürich
ml@nicer.org